Here we further investigated the cellular mechanisms involved in such drug resistance and show that, in HCT116 human colorectal adenocarcinoma cells in which TP53 was genetically ablated (HCT116-TP53KO), over-expression of constitutively active MAPK14/p38 decreases cell sensitivity to SN-38 (the active metabolite of Irinotecan), inhibits cell proliferation and induces survival-autophagy. Since autophagy is known to facilitate cancer cell resistance to chemotherapy and radiation treatment, we then investigated the relationship between MAPK14/p38, autophagy and resistance to irinotecan. We demonstrate that induction of autophagy by SN38 is dependent on MAPK14/p38 activation. Finally, we show that inhibition of MAPK14/p38 or autophagy both sensitizes HCT116-TP53KO cells to drug therapy. Our data prove that the two effects are interrelated, since the role of autophagy in drug resistance required the MAPK14/p38. Our results highlight the existence of a new mechanism of resistance to camptothecin-related drugs: upon SN38 induction, MAPK14/p38 is activated and triggers survival-promoting autophagy to protect tumor cells against the cytotoxic effects of the drug. Colon cancer cells could thus be sensitized to drug therapy by inhibiting either MAPK14/p38 or autophagy.
Introduction
Colorectal cancer (CRC) is the third most frequent malignancy in Western countries. carcinoma cell lines and tissue display lower level of Beclin1 than normal breast epithelia. 9 However, after a cancer is established, autophagy may help cancer cells to survive in the presence of growth-limiting conditions, such as nutrient depletion and hypoxia, or cytotoxic drugs.
Here, we further investigated the functional role of MAPK14/p38 in the development of irinotecan resistance in HCT116 cells in which TP53 was deleted (HCT116-TP53KO cells), because TP53 is often mutated in CRC and p53 is a p38 target. We show that, in HCT116-TP53KO cells, over-expression of constitutively active MAPK14/p38 reduces their sensitivity to SN38 and impairs cell proliferation. Moreover, MAPK14/p38 over-expression leads to an increase in autophagy and cell survival. Finally, MAPK14/p38 or autophagy inhibition increases the sensitivity of HCT116-p53 KO cells to SN38.
RESULTS

The MAPK14 is involved in SN38 resistance in HCT116-p53 KO cells
We already showed that p38, particularly MAPK14 and MAPK11, is involved in resistance to irinotecan and to its active metabolite SN38. 6 Since one of the p38 targets is p53 and TP53 is frequently mutated in colon cancer, we now investigated whether p38 was also involved in irinotecan resistance in cells depleted of TP53. To this aim, each of the four p38 isoforms (MAPK14, MAPK11, MAPK12 and MAPK13) was down-regulated by ShRNA (Fig. 1A ) in HCT116 colorectal cancer cells, in which TP53 was genetically ablated (HCT116-TP53KO cells) and the effect of their silencing on the sensitivity to SN38 was tested with the SRB assay (Fig. 1B) . Silencing of the MAPK11, MAPK12 and MAPK13 had no impact on SN38 sensitivity in HCT116-TP53KO cells. On the contrary, SN38 cytotoxicity was more elevated in cells in which MAPK14 was silenced by two different hairpins (shMAPK14 and ShMAPK14bis) ( lower IC 50 (50% inhibitory concentration) (ShLuc 1.9 nM, shMAPK141.2 p-value: 0.03and ShMAPKbis 1.1 p-value: 0.0014). This result suggests that MAPK14 loss is sufficient to increase the sensitivity of HCT116-TP53KO cells to SN38.
Then, HCT116-TP53KO cells were infected with retroviruses expressing constitutively active (CA) variant of each p38 isoform 10 and their sensitivity to SN38 was again tested using the SRB assay. Expression of the CA p38 variants was monitored by western blotting with an anti-HA antibody (Fig. 1C ) and activity by Kinase Assay (Fig. 1D ). Cells expressing constitutively active MAPK14 (HCT116-TP53KO-MAPK14CA cells) were more resistant to SN38 than control cells that were transduced with empty vector (EV) (HCT116-TP53KO-EV cells), as evidenced by their higher IC 50 (2.6 nM and 1.3 nM, respectively, p= 0.015) ( Then, we investigated whether SN38 induces p38 phosphorylation in HCT116-TP53KO.
Western blot analysis using phospho-specific p38 antibody showed an increase of p38 phosphorylation following SN38 treatment in HCT116-TP53KO (Fig. 1F ). Overall these results show that MAPK14 is responsible for SN38 resistance and are in accordance with our previous results obtained in the parental HCT116 cell line. 6 
Expression of constitutively active MAPK14 inhibits proliferation of HCT116-TP53KO cells
To further delineate the effects of the expression of constitutively active MAPK14 in HCT116-TP53KO cells, we first compared the cell growth rates of HCT116-TP53KO-MAPK14-CA and HCT116-TP53KO-EV cells ( Fig. 2A) . Growth rates were assessed for both cell lines 14 days after retroviral transduction. In HCT116-TP53KO-MAPK14-CA cells, cell inserm-00705786, version 1 -8 Jun 2012
growth was greatly reduced, with a doubling time of 89.8 hours compared to HCT116-TP53KO-EV, 33.3 hours (p-value: 9.9 10 -6 ) ( Fig. 2A and 2B ). Since MAPK-CA overexpression did not influence cell proliferation in parental HCT116 cells (Supp. Fig. 1A ), its negative effect on the growth rate of HCT116-TP53KO cells might be linked to the absence of TP53.
As these results were obtained by counting the cells at different intervals, they could be due to increased cell death or inhibition of cell proliferation. We thus compared the . 1C ). These results indicate that HCT116-TP53KO-MAPK14-CA cells were not dying, but rather slow down their proliferation. As p38 can induce cell senescence, we then investigated whether HCT116-TP53KO-MAPK14-CA cells were senescent. 11, 12 The number of cells that were positive for -galactosidase activity (a marker of cell senescence) was similar in control and HCT116-TP53KO-MAPK14-CA cells (Fig. 2E ), indicating that senescence is not the mechanism by which HCT116-TP53KO-MAPK14-CAcells proliferate slowly.
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p21 is responsible for the proliferation decrease of HCT116-TP53KO-MAPK14-CA
We then examined the cell cycle distribution of control HCT116-TP53KO-EV and HCT116-TP53KO-MAPK14-CA cells using BrdU staining and flow cytometry at day 14 after transduction (the time we observed the cell growth inhibition) (Fig. 3A) . that BrdU incorporation was higher in HCT116-TP53KO-Shp21-MAPK14-CA than in the control HCT116-TP53KO-ShLuc-MAPK14-CA cells (Fig.3G ). This result demonstrated that the reduction of cell growth was due, at least in part, to the overexpression of p21 in HCT116-TP53KO-MAPK14-CA. In conclusion, MAPK14 over-expression in HCT116-TP53KO cells leads to p21 over-expression and slowing down of cell proliferation.
Expression of constitutively active MAPK14induces autophagy in HCT116-TP53KO-
MAPK14-CA cells
While examining the morphology of HCT116-TP53KO-MAPK14-CA cells at day 14 after retroviral infection, we observed that they displayed large cytoplasmic vacuoles (Fig. 4A ).
This feature together with the observation that HCT116-TP53KO-MAPK14-CA cells grow slowly, but were neither apoptotic nor senescent prompted us to investigate whether they exhibited autophagy characteristics. First, the expression of the two forms of the microtubuleassociated Light Chain 3 protein (LC3) was assessed by immunoblotting. Indeed, during autophagy, cytosolic LC3-I is converted into the membrane-bound lipidated LC3-II, which is detected by a mobility shift during electrophoresis. Higher LC3-II expression was observed only in HCT116-TP53KO-MAPK14-CA cells at day 14 after transduction ( Fig. 1D ). We also observed high level of LC3-II from day 7 to day 21 after retroviral transduction of the MAPK14-CA plasmid in TP53-deficient H1299 lung cancer cells (Fig. 4B, low panel) . Then, to confirm the induction of autophagy in HCT116-TP53KO-MAPK14-CA cells, cells were analyzed by electron microscopy (Fig. 4C) (Fig. 4D) .
To evaluate the relationship between reduction of growth rate and autophagy induction, we have performed LC3 Western Blot analysis on HCT116-TP53KO-ShLuc-MAPK14-CA and HCT116-TP53KO-Shp21-MAPK14-CA (Fig. 4E ). We could observe that the LC3-II expression is not reduced in HCT116-TP53KO-Shp21-MAPK14-CA, while the proliferation is increased (Fig. 3F and 3G ), indicating that the proliferation and the autophagy induction may not be connected. These results demonstrate that over-expression of constitutively active MAPK14 inhibits cell proliferation and induces autophagy in TP53-depleted colon cancer cells. As a consequence, decrease in cell proliferation and autophagy induction can both be involved in MAPK14 induced resistance to SN38.
MAPK14-induced autophagy promotes survival of HCT116-p53 KO-MAPK14-CA cells
Autophagy is a dynamic process that begins with the generation of autophagosomes and terminates with their degradation in lysosomes and corresponds to the autophagic flux. To examine the autophagic flux in HCT116-TP53KO-MAPK14-CA cells, we monitored the expression of p62, which is incorporated into the completed autophagosome and degraded in autolysosomes. 15 Western blot analysis of p62 expression ( Bafilomycin: 47.5%, p=0.00003). These results were confirmed by down-regulating the expression of ATG5 and ATG7, two genes which are essential for autophagy, with specific siRNAs (Fig. 5E ). Indeed, down-regulation of ATG5 or ATG7 strikingly increased cell mortality in HCT116-TP53KO-MAPK14-CA cells (but not in in HCT116-TP53KO-EV cells)
in comparison to cells transfected with control siRNAs (siCT) (siATG5: 88% of dead cells, p=1 10 -8 ; siATG7: 90%, p=1.9 10 -7 ). In conclusion, these data demonstrate that overexpression of constitutively active MAPK14 induces survival-promoting autophagy in HCT116-TP53KO cells.
Autophagy is involved in SN38 resistance of p53-defective cancer cells
As MAPK14 over-expression in HCT116-TP53KO cells induces survival autophagy, we then investigated whether autophagy could play a role in the mechanism of cancer cell resistance to SN38. We first assessed autophagy induction with SN38 by LC3 labelling immunofluorescence in HCT116 (Supp. Fig. 2A ) and HCT116-TP53KO ( 
inserm-00705786, version 1 -8 Jun 2012
We then inhibited autophagy in HCT116, HCT116-TP53KO and SW480 cells and tested the effect of such inhibition on the sensitivity to SN38. SW480 cells were transfected with ATG5-or ATG7-specific siRNAs and SN38 cytotoxicity, assessed by SRB assay, was evaluated. We found that SN38 IC 50 was lower in cells in which autophagy was inhibited (Fig. 6D ) than in cells transfected with control siRNAs (siCT), indicating that autophagy is involved in SN38 resistance. We confirmed the impact of autophagy inhibition on SN38 cytotoxicity in HCT116p53KO cells with siATG transfection and 3MA treatment, using SRB (Fig. 6E) , clonogenic ( Fig. 6F ) and trypan blue exclusion assay (Fig. 6G) , confirming the protective role of autophagy on SN38 treatment. At the opposite, autophagy inhibition with siATG transfection or 3MA treatment was not able to impact on SN38 cytotoxicity in HCT116 cells (Supp. Fig. 2D , 2E, 2F), indicating that SN38 induces autophagy-mediated survival only in TP53 defective cells. In conclusion, similarly to what we observed following inhibition of MAPK14 6 inhibition of autophagy enhanced the cytotoxic effect of SN38, but only in cells where p53 is altered.
As we have previously observed that the two other drugs used to treat colorectal cancer, 5-Fluorouracile (5-FU) and Oxaliplatin, induced p38 phosphorylation, we asked whether these drugs can induce autophagy, and if autophagy has an impact on their cytotoxicity (Supp. Fig 3) . We first determined IC50 concentrations for both drugs using SRB assay (Supp. alone, but did not have any effect on HCT116-TP53KO-ShMAPK14 cells (Fig. 7A ). This result clearly indicates that MAPK14 is necessary for SN38-mediated induction of autophagy.
In addition to MAPK14, we have also performed inhibition of MAPK11MAPK12and
MAPK13and treated the HCT116-TP53KO cells with SN38. LC3-II Western blot analysis indicates that inhibition of MAPK11, MAPK12 and MAPK13 did not inhibit the SN38 autophagy induction (Fig. 7B) . Moreover, we have treated HCT116-ShLuc and HCT116-MAPK14 cells with SN38 and we found that autophagy is not reduced in HCT116-ShMAPK14 (Supp. Fig. 2C ). In conclusion, MAPK14 is the main p38 isoform involved in autophagy induction by SN38 (Fig. 7A) , and exclusively in a TP53KO context.
We then evaluated the impact of autophagy inhibition on the sensitivity to SN38 of HCT116-TP53KO-ShMAPK14 cells. HCT116-TP53KO-ShLuc and HCT116-TP53KO-ShMAPK14 cells were either treated with SN38 and SN38+3MA ( promoting autophagy are part of the same mechanism induced by SN38, and that hindering MAPK14 activity will block the SN38 effect on survival-promoting autophagy. In conclusion MAPK14 confers SN38 resistance to HCT116-TP53KO cells by inducing survival autophagy.
DISCUSSION
In this study, we demonstrate the role of MAPK14 in the resistance to SN38, the active metabolite of irinotecan, in TP53-depleted HCT116 colorectal cancer cells. Moreover we show that over-expression of constitutively active MAPK14 induces survival autophagy in colorectal cancer cells depleted of TP53 and that inhibition of autophagy in such cells enhances the cytotoxic effect of SN38.
We previously reported that MAPK14 is involved in irinotecan resistance in in vivo and in vitro experimental settings and in clinical samples. 6 Here we confirm this finding by
showing that over-expression of constitutively active MAPK14makes also TP53-depleted colorectal cancer cells more resistant to irinotecan, and conversely its down-regulation sensitizes these cells. This new finding indicates that the involvement in irinotecan resistance is not dependent on the p53 status of the cancer cells. This suggests that p38 inhibitors could be used as an adjuvant therapy to potentiate the efficacy of irinotecan-based chemotherapies, whatever the p53 status of the tumor.
Moreover, we report that over-expression of MAPK14 leads to cell growth inhibition of HCT116-TP53KO cells. Previous works have already reported that MAPK14 can cause cell cycle arrest via two pathways. Specifically, after UV radiation, MAPK14 can phosphorylate and inhibit the phosphatase Cdc25B which in turn inhibits the Cyclin B/cdc2 complex needed for cell cycle progression. 16 The other pathway involves the phosphorylation and activation of p53 and induction of the p53-dependent G2/M checkpoint. 13 Here, we show that MAPK14 over-expression leads to an increase of p21 protein (but not of mRNA) level Growing evidence indicates that chemotherapy induces autophagy in a variety of tumor cells, 25 leading either to tumor protection or tumor cell death. In the present study, we demonstrate that, in TP53 defective colorectal cancer cells, camptothecin-derivative drugs induce survival-promoting autophagy via MAPK14 activation. In conclusion, it appears that survival-promoting autophagy, which is responsible for resistance to chemotherapy, is dependent on the TP53 status of the tumor and p38 activation. As autophagy inhibitors could be used to overcome camptothecin-related drug resistance, it is crucial to determine the TP53 status of the patients and the level of p38 activation by the drug.
Materials and Methods
Cell lines and reagents:
The HCT116 (CCL-247), SW480 (CCL228) human colon adenocarcinoma cell lines and the H1299 (CRL5803) human non-small cell lung cancer cell
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line from ATCC were grown in RPMI 1640 supplemented with 10% foetal calf serum (FCS) and 2 mmol/L l-glutamine at 37°C in a humidified atmosphere with 5% CO 2 . HCT116-TP53KO cells, in which TP53 had been genetically ablated, were kindly given by Bert
Volgestein. SN38 was provided by Sanofi-Aventis.
Drug sensitivity:
Cell growth inhibition and cell viability after SN38 treatment were assessed using the sulforhodamine B (SRB) (Sigma: S-9012) assay as previously described and called SRB assays. 
RNA preparation and RT-Q-PCR:
Total RNA was isolated from HCT116-TP53KO-EV and -MAPK14-CA cells using the RNeasy ® mini Kit (Qiagen, 74104) with an additional DNAse digestion step (Qiagen, 79254). RNA was quantified by UV spectroscopy. Total RNA (1 μg) was reverse transcribed using the SuperScript III reverse transcriptase (Invitrogen, 1808004). Real-time quantitative PCR was performed using the LC480 (Roche Diagnostics)
according to the manufacturer's instruction. The amplification specificity was verified by using the melting curve analysis. Real-time PCR values were determined by reference to a standard curve that was generated by real-time PCR amplification of a serially diluted cDNA sample using primers specific for p21, ATG5, ATG7 and Hypoxanthine Phosphorybosyl
Transferase (HPRT). The quantification data were normalized to the amplification data for the reference gene HPRT.
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Apoptosis assay: Cells were seeded in 25 cm 2 flasks (10 5 cells/flask). After 48 hours, they were labelled with fluorescein isothiocyanate (FITC)-labeled Annexin V and 7AAD (Coulter, PN IM3614) to determine the number of apoptotic cells.
siRNA and transfection procedures: siRNA oligonucleotides targeting ATG5, ATG7 and control non-targeting constructs (siCT) (SR-CL000-005) were obtained from Eurogentec.
Transfections were performed using Oligofectamine (Invitrogen, 12252011) according to the manufacturer's instructions. Briefly, 2x10 5 cells were plated in each well of a 6-well plate and incubated overnight. A mixture of 3µg siRNA and Oligofectamine diluted in OptiMEM (31985) was added for 6 hours, followed by incubation in regular medium. Cells were harvested 96 hours after siRNA transfection.
Kinase assay
The p38 kinase assay was performed using the non-radioactive p38 MAPK Assay Kit from Cell Signaling Technology (9820) with 2µg of p38 isoforms. MAPK14 mutant is p38 Statistical analysis: Analysis of quantitative data was performed by using the Student's t-test.
Differences were considered statistically significant, when P < 0.05. 
